NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/04/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization227.36 mln
Float19.12 mln
Earnings Date08/12/2026
EPS
2.30
Solid
P / E
5.09
Undervalued
Piotroski F-Score
7
/ 9
Strong
Beneish M-Score
56.33
Highly suspicious
Relative Strength
62
/ 100
Outperforming
Debt / Equity
0.06
Debt-free
Business Description
Keros Therapeutics is a US-based drug development company focused on treating diseases caused by faulty protein signaling in the body. Its two lead drugs, rinvatercept and elritercept, are currently being tested in clinical trials for serious conditions including muscular dystrophy, ALS, and certain blood disorders. The company works alongside partners Hansoh Healthtech and Takeda Pharmaceuticals to bring these treatments to market. Founded in 2015 and based in Lexington, Massachusetts, Keros continues to build its pipeline with the goal of addressing significant unmet medical needs.
